Stability Indicating HPLC Method for Drugs Indicated for Helicobacter Pylori-associated Ulcers

Authors

  • H.M. Hafez Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
  • A.A. Elshanawany Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
  • L.M. Abdelaziz Faculty of Pharmacy, Zagazig University, Zagazig, Egypt
  • M.S. Mohram Faculty of Pharmacy, Zagazig University, Zagazig, Egypt

DOI:

https://doi.org/10.37591/(rrjops).v6i1.922

Abstract

 

Triple therapy regimen that comprises a proton pump inhibitor likes Omeprazole, antibiotics like Doxycycline and Tinidazole can be used for treatment of peptic ulceration which is caused by H. pylori. A validated HPLC method was developed as a stability-indicating HPLC method for these drugs and its impurities. New method overcame interference between Doxycycline and its epimer on achiral column by using a chiral mobile phase. The method was performed on Phenomenex BDS HYPERSIL C18 5 μm 100A (250x4.6 mm) and the mobile phase consisted of (1S)-(+)-Campher-10-sulfonic acid (0.01M) and Edetate disodium (0.001M) (pH=4.5) Acetonitrile which pumped at a flow rate 1.2 ml/min in gradient manner at 40°C. 20 µl of drugs sample solutions were monitored at wavelength 310 nm. Tinidazole, Doxycycline and Omeprazole and Trio capsule bulk powders were stressed under different conditions in forced degradation studies. Method validation was developed following the recommendations for analytical method validation of International Conference on Harmonization (ICH) and Food and Drug Administration (FDA) organizations.

 

Keywords: Tinidazole, Doxycycline, Omeprazole, chiral mobile phase, stability indicating assay-ulcer treatment

Downloads

Published

2021-01-12

Issue

Vol. 6 No. 1 (2015)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.